Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) Income from Continuing Operations (2020 - 2026)

Design Therapeutics' Income from Continuing Operations history spans 2 years, with the latest figure at 11127000.0 for Q4 2021.

  • On a quarterly basis, Income from Continuing Operations fell 188.19% to 11127000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was 35831000.0, a 330.14% decrease, with the full-year FY2025 number at 69792000.0, down 40.74% from a year prior.
  • Income from Continuing Operations hit 11127000.0 in Q4 2021 for Design Therapeutics, up from 11337000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for DSGN hit a ceiling of 623000.0 in Q1 2020 and a floor of 11337000.0 in Q3 2021.